Atai Beckley N.V (ATAI)

Atai Life Sciences and Beckley Psytech announced positive topline results from their Phase 2b study of BPL-003 in patients with treatment-resistant depression, leading to their strategic combination. Atai Life Sciences reported second-quarter 2025 financial results and corporate updates. Atai Life Sciences and Beckley Psytech Limited reported positive Phase 2a data demonstrating improved outcomes with a two-dose induction regimen of BPL-003 in patients with treatment-resistant depression. Needham initiated coverage on Atai Life Sciences N.V. with a "Buy" recommendation and a price forecast of $12. Atai Life Sciences and Beckley Psytech announced the successful completion of their strategic combination to create AtaiBeckley. AtaiBeckley announced positive topline data from the Phase 2b Open-Label Extension Study of BPL-003, supporting the safety and efficacy of a second dose in patients with treatment-resistant depression. AtaiBeckley reported third-quarter 2025 financial results and recent corporate highlights. The company changed its name from ATAI Life Sciences N.V. to Atai Beckley N.V.

Specific demand seasonality for Atai Beckley N.V.'s products is not detailed. Demand for its products, once approved, will likely be driven by the prevalence of the conditions they treat rather than seasonal patterns. The company's focus is on clinical trials and drug development, not seasonal sales.

Atai Beckley N.V., formerly ATAI Life Sciences N.V., is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders, operating within the biotechnology sector. Its pipeline includes psychedelic and non-psychedelic compounds such as BPL-003 for treatment-resistant depression and alcohol use disorder, RL-007 for cognitive impairment associated with schizophrenia, ELE-101 for major depressive disorder, VLS-01 to treat TRD, EMP-01 for social anxiety disorder, EGX-A & EGX-B for TRD, COMP360 for psilocybin therapy, and GRX-917 for anxiety, depression, and neurological disorders.

Atai Beckley N.V. is involved in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company has an international strategy with research centers and collaborations across Europe, North America, and other key markets. Its headquarters are in Amstelveen, The Netherlands.

Atai Beckley N.V. has a positive brand reputation in the biotechnology and mental health research sectors due to its focus on innovative treatments for psychiatric and neurological disorders. Positive clinical trial results for BPL-003, the strategic combination with Beckley Psytech, analyst coverage from Needham with a "Buy" rating, dedication to unmet medical needs, and successful capital raising have contributed to this positive perception. No significant negative events impacting the company's reputation were found.

Atai Beckley N.V.'s ownership includes institutional investors holding approximately 1.77% to 13.63% of the stock, insiders owning approximately 0.37% to 21.24%, and retail investors holding approximately 75.31%. Major owners include Apeiron Investment Group Ltd., Galaxy Group Investments LLC, UBS Asset Management AG, Adage Capital Management, L.P., ARK Investment Management LLC, Morgan Stanley Investment Management Inc., Presight Capital Management Company, L.L.C., Apeiron Presight Capital Fund II, L.P., Morgan Stanley, and Millennium Management LLC. Top Mutual Fund Holders include ARK ETF Trust - ARK Genomic Revolution ETF, T. Rowe Price Small-Cap Stock Fund, Inc., and AdvisorShares Trust - AdvisorShares Psychedelics ETF.